Clinical Trials Browser

OTHER × Carcinoma, Non-Small-Cell Lung × Crizotinib × Clear all

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT06563999 2024-12-10

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04084717 2024-07-16

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06254599 2024-02-12

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT03646994 2023-12-27

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT03647111 2023-12-27

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03088930 2022-02-11

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Phase 2 Completed

3 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT01998126 2018-04-02

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02499614 2017-10-25

METROS

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02277457 2016-06-24

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Phase EARLY_PHASE1 Withdrawn

Carcinoma, Non-Small-Cell Lung